Background Eculizumab is a lifesaving yet expensive drug for atypical haemolytic uraemic
syndrome (aHUS). Current guidelines advise a fixed-dosing schedule, which can be …

Background The introduction of eculizumab has significantly improved the outcome of
patients with atypical haemolytic uraemic syndrome (aHUS). Because of the risk of relapse …

Objective To describe how maintenance eculizumab sustains improved renal function in
severe atypical hemolytic uremic syndrome (aHUS). Case report A previously described 50 …

Background Eculizumab modifies the course of disease in patients with atypical haemolytic
uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe …

Aims Eculizumab is an anti‐C5 monoclonal antibody approved for rare diseases including
atypical haemolytic–uraemic syndrome. The maintenance phase dosing regimen is identical …

The complement inhibitor, eculizumab, has revolutionised the management of atypical
haemolytic uraemic syndrome (aHUS), although the optimum treatment duration is debated …

Background Kidney transplantation in patients with atypical haemolytic uraemic syndrome
(aHUS) is frequently complicated by recurrence of aHUS, often resulting in graft loss …

Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening
disorder for which eculizumab is the only approved treatment. Life-long treatment is …

Effective treatments for atypical haemolytic uraemic syndrome (aHUS) have long been
lacking, but the discovery that complement dysregulation is a major risk factor for this …

Background Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic
uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may …